ATE484501T1 - Als protein-kinase-inhibitoren nutzbare benzimidazole - Google Patents

Als protein-kinase-inhibitoren nutzbare benzimidazole

Info

Publication number
ATE484501T1
ATE484501T1 AT06787944T AT06787944T ATE484501T1 AT E484501 T1 ATE484501 T1 AT E484501T1 AT 06787944 T AT06787944 T AT 06787944T AT 06787944 T AT06787944 T AT 06787944T AT E484501 T1 ATE484501 T1 AT E484501T1
Authority
AT
Austria
Prior art keywords
protein kinase
benzimidazoles
usable
kinase inhibitors
compounds
Prior art date
Application number
AT06787944T
Other languages
German (de)
English (en)
Inventor
Hayley Binch
Michael Mortimore
Daniel Robinson
Dean Stamos
Simon Everitt
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE484501T1 publication Critical patent/ATE484501T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT06787944T 2005-07-26 2006-07-21 Als protein-kinase-inhibitoren nutzbare benzimidazole ATE484501T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70239905P 2005-07-26 2005-07-26
PCT/US2006/028149 WO2007015923A2 (en) 2005-07-26 2006-07-21 Benzimidazoles useful as inhibitors of protein kinases

Publications (1)

Publication Number Publication Date
ATE484501T1 true ATE484501T1 (de) 2010-10-15

Family

ID=37680602

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06787944T ATE484501T1 (de) 2005-07-26 2006-07-21 Als protein-kinase-inhibitoren nutzbare benzimidazole

Country Status (17)

Country Link
US (1) US8076343B2 (enExample)
EP (2) EP1937667B1 (enExample)
JP (2) JP5255438B2 (enExample)
KR (1) KR20080034483A (enExample)
CN (1) CN101291927A (enExample)
AT (1) ATE484501T1 (enExample)
AU (1) AU2006276088A1 (enExample)
CA (1) CA2616159A1 (enExample)
DE (1) DE602006017574D1 (enExample)
ES (1) ES2351357T3 (enExample)
IL (1) IL188942A0 (enExample)
NO (1) NO20080967L (enExample)
NZ (1) NZ566021A (enExample)
RU (1) RU2415853C2 (enExample)
TW (1) TW200745088A (enExample)
WO (1) WO2007015923A2 (enExample)
ZA (1) ZA200800992B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2920996A1 (en) 2007-10-19 2009-04-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
US9336046B2 (en) 2012-06-15 2016-05-10 International Business Machines Corporation Transaction abort processing
US9512136B2 (en) * 2012-11-26 2016-12-06 Universal Display Corporation Organic electroluminescent materials and devices
WO2014147203A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014170421A1 (en) * 2013-04-19 2014-10-23 F. Hoffmann-La Roche Ag Serine/threonine kinase inhibitors
ITUA20164278A1 (it) * 2016-06-10 2017-12-10 International Soc For Drug Development S R L COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
CN112552287B (zh) * 2020-12-16 2021-11-30 北京华氏精恒医药科技有限公司 一种吲哚类衍生物药物制剂及其制备方法
WO2023116888A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143157A0 (en) 1998-11-17 2002-04-21 Kumiai Chemical Industry Co Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural bactericides
JP4535350B2 (ja) * 1998-11-17 2010-09-01 クミアイ化学工業株式会社 ピリミジニルベンズイミダゾール誘導体及び農園芸用殺菌剤
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
DE60217322T2 (de) * 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
WO2003099811A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
CL2003002353A1 (es) * 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB2432834A (en) * 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors

Also Published As

Publication number Publication date
CA2616159A1 (en) 2007-02-08
IL188942A0 (en) 2008-04-13
CN101291927A (zh) 2008-10-22
EP1937667B1 (en) 2010-10-13
JP2009502921A (ja) 2009-01-29
RU2415853C2 (ru) 2011-04-10
KR20080034483A (ko) 2008-04-21
ES2351357T3 (es) 2011-02-03
WO2007015923A2 (en) 2007-02-08
EP2336122A1 (en) 2011-06-22
WO2007015923A8 (en) 2008-04-03
ZA200800992B (en) 2009-09-30
AU2006276088A1 (en) 2007-02-08
EP1937667A2 (en) 2008-07-02
JP5255438B2 (ja) 2013-08-07
NZ566021A (en) 2011-03-31
RU2008106949A (ru) 2009-09-10
WO2007015923A3 (en) 2007-04-19
EP2336122B1 (en) 2014-05-14
US8076343B2 (en) 2011-12-13
JP2013082757A (ja) 2013-05-09
TW200745088A (en) 2007-12-16
NO20080967L (no) 2008-04-22
DE602006017574D1 (de) 2010-11-25
US20070099920A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
NO20080967L (no) Benzimidazoler nyttige som inhibitorer av proteinkinaser
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
SG166827A1 (en) Aminopyrimidines useful as kinase inhibitors
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TW200633980A (en) Pyridones useful as inhibitors of kinases
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE542814T1 (de) Pyrazinkinaseinhibitoren
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties